Medication info
Januvex Tablets 50/850 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Januvex Tablets 50/850 mg (Sitagliptin Hydrochloride Monohydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›850mg / 1 tabletSitagliptin Hydrochloride Hydrate›56.7mg / 1 tablet
Manufacturer / importer
Seoul Pharmaceuticals Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
60 tablets/box [10 tablets/PTP x 6]
Approval status
Active

MFDS item code 202301951 · Approved 2023.06.26 · Insurance code 652904680

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The starting dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).

Ingredients

Manufacturer
Seoul Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps effectively control blood sugar levels in patients with type 2 diabetes. Sitagliptin and metformin work together to complement dietary management and exercise therapy while improving blood sugar levels. This can enhance treatment effectiveness for patients whose blood sugar is difficult to manage. This medication is used for blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

For antidiabetic therapy, the dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of the individual components: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with food. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The starting dose of this medication should be determined according to the patient's current treatment regimen. 1. Patients not currently treated with metformin: For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the starting dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Receive This Medication). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg); the starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral glucose-lowering medication to this medication. Any change in the treatment regimen for type 2 diabetes may cause a change in glycemic control; therefore, caution and appropriate monitoring are required. Patients with renal impairment This medication may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2) who have no other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication must be discontinued immediately. Patients with hepatic impairment This medication must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Receive This Medication).

Precautions

This medication consists of two components, each with different precautions. First, the sitagliptin component may rarely cause serious allergic reactions. Symptoms of such reactions may include difficulty breathing, swelling of the face or neck, and severe skin rashes. If such symptoms occur, immediately stop taking this medication and consult a doctor. Additionally, sitagliptin may cause inflammation of the pancreas, so if abdominal pain, vomiting, or nausea occurs, seek medical attention promptly. Second, the metformin component can cause a rare but potentially life-threatening condition known as lactic acidosis. This condition may present with symptoms such as muscle pain, difficulty breathing, lethargy, and abdominal pain; if such symptoms occur, immediately discontinue the medication and contact a medical facility. This medication should not be administered to patients with severely impaired kidney function or those with serious infections, dehydration, or acute heart disease. Moreover, pregnant or nursing women should avoid its use. During treatment, regular kidney function tests should be conducted, and elderly patients should be especially cautious as they are at higher risk for impaired kidney function. Furthermore, taking this drug in conjunction with other diabetes medications or alcohol may increase the risk of hypoglycemia, thus blood sugar levels should be frequently monitored and dosage adjustments should be made as needed in consultation with a doctor. Before undergoing surgery or imaging tests involving contrast agents, this medication should be temporarily discontinued, and it should only be resumed after confirming normal kidney function following the tests. Side effects such as diarrhea, nausea, vomiting, headache, upper respiratory infection, may occur during treatment. If any symptoms are severe or persistent, consult a physician. Lastly, if any unusual symptoms such as rapid weight loss, loss of appetite, skin rashes, joint pain, or blistering skin disorders occur during treatment, promptly inform healthcare personnel.

Side effects

  • Anaphylaxis
  • angioedema
  • Stevens-Johnson syndrome
  • acute pancreatitis
  • lactic acidosis
  • hypoglycemia
  • diarrhea
  • upper respiratory tract infection
  • headache
  • nausea
Show 22 more
  • vomiting
  • abdominal pain
  • nasopharyngitis
  • constipation
  • severe and disabling arthralgia
  • blistering similar to pemphigus
  • myalgia
  • limb pain
  • back pain
  • interstitial lung disease
  • pruritus
  • thrombocytopenia
  • rhabdomyolysis
  • dyspnea
  • unstable angina
  • dizziness
  • decreased appetite
  • gastrointestinal disturbances
  • itching
  • severe hypoglycemia
  • dermatitis
  • weight loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is advisable to keep the storage temperature between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the medication's effectiveness for a prolonged period.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP x 6]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.